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Abstract
Aim Our objective was to assess the performance of the
cobas test versus comparators for KRAS mutation status
and predicting clinical response to anti-epidermal growth
factor receptor (EGFR) therapy in patients with metastatic
colorectal cancer (mCRC).
Methods mCRC samples from 398 patients from Roche
study NO16968 (XELOXA) and 82 supplemental samples
were tested with the cobas KRAS mutation test (cobas
test), the therascreen KRAS RGQ PCR kit test (ther-
ascreen test), and Sanger sequencing as the reference
method for detecting mutations in codons 12/13.
Results For 461 eligible samples, the cobas test, ther-
ascreen test, and sequencing had invalid results for 5.2,
10.8, and 2.6 % of specimens, respectively. Valid cobas
and therascreen test results had similar KRAS mutation-
positive rates (37.3 vs. 36.3 %, respectively); sequencing
was 28.5 %. Positive and negative percent agreement
(PPA/NPA) between the cobas test and sequencing was
96.9 % (95 % confidence interval [CI] 92.2–98.8), and
88.7 % (95 % CI 84.7–91.8), respectively. PPA/NPA
between the cobas and therascreen tests was 93.3 % (95 %
CI 88.1–96.3) and 96.5 % (95 % CI 93.5–98.1), respec-
tively. Bridging analysis from NCIC-CO.17 and
NCT00113763 using the cobas test yielded modeled hazard
ratios for overall survival and progression-free survival
(PFS) of 0.558 (95 % CI 0.422–0.752) and 0.413 (95 % CI
0.304–0.550), respectively, for cetuximab and 0.989 (95 %
CI 0.778–1.299) and 0.471 (95 % CI 0.360–0.626),
respectively, for panitumumab, demonstrating significant
efficacy in the KRAS-negative population for PFS.
Conclusion The cobas test showed similar accuracy to
the therascreen test for detecting KRAS mutations and
could appropriately identify mCRC patients ineligible for
anti-EGFR therapy as demonstrated by bridging analysis
results.
Key Points
Targeted therapy with cetuximab provides a survival
benefit to patients with metastatic colorectal cancer
(mCRC) whose tumors harbor a wild-type KRAS
gene.
To expand the available diagnostic options for
testing the anti-epidermal growth factor receptor
(EGFR) therapy response of patients with mCRC,
the current study compared the performance of the
cobas test with that of the therascreen test and Sanger
sequencing. Bridging analysis of existing published
data was performed through a method comparison
study to validate clinical value.
The cobas test demonstrated an analytical
performance comparable to that of the therascreen
test based on positive, negative, and overall percent
agreements and also demonstrated clinical utility in
predicting clinical response to anti-EGFR therapy in
patients with KRAS wild-type mCRC.
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1 Introduction
In vitro diagnostic (IVD) tests are playing an increasingly
important role in selecting patients with cancer for targeted
therapies, both to direct treatment to eligible patients and to
avoid prescribing unnecessary and potentially detrimental
therapies. The CO.17 pivotal study and subsequent analy-
ses showed that cetuximab, a monoclonal antibody that
inhibits activity of the epidermal growth factor receptor
(EGFR), provided a survival benefit to patients with
advanced colorectal cancer (CRC), i.e., those for whom all
chemotherapy for CRC had failed and no other standard
anticancer therapy was available. Compared with best
supportive care (BSC) alone, treatment with cetuximab
yielded a significant improvement in overall survival (OS)
[1]. Subsequent analyses showed that the survival benefit
applied only to patients with metastatic colorectal cancer
(mCRC) whose tumors harbored a wild-type KRAS gene,
and tumors with a mutation in codon 12 or 13 of exon 2 of
the KRAS gene were insensitive to anti-EGFR therapy [2–
5]. Several prospective randomized controlled trials and
retrospective analyses have confirmed this conclusion [4,
6–9]. Similar results were observed for another anti-EGFR
monoclonal antibody, panitumumab, in study
NCT00113763. In this study, panitumumab plus BSC
yielded a significant improvement in progression-free sur-
vival (PFS) compared with BSC alone in the subgroup of
patients with wild-type KRAS [10]. Also, there was no
significant improvement in the subgroup with KRAS
mutation [10].
The mechanism of anti-EGFR failure in patients with
EGFR-expressing tumors can be explained by the fact that
KRAS acts downstream of EGFR, and KRAS-activating
mutations can supersede EGFR inhibition.
Recent studies have shown that mutations in KRAS
outside exon 2 and mutations in NRAS are also associated
with low response rates for cetuximab and panitumumab
therapy [11–13]. It is now recognized that KRAS and NRAS
mutations in exons 2, 3, and 4 are predictive of resistance
to anti-EGFR therapy. Based on these findings, the
National Comprehensive Cancer Network (NCCN) guide-
lines strongly recommend KRAS/NRAS genotyping of
tumor tissue in all patients with mCRC [14]. Also, limiting
EGFR-directed treatment to patients with wild-type KRAS
is supported by clinical treatment guidelines from the
NCCN, the American Society of Clinical Oncology, and
the European Society for Medical Oncology [14–16].
The therascreen KRAS RGQ PCR Kit (therascreen
test) for use with the Rotor-Gene Q MDx instrument was
approved by the US FDA in July 2012 for determining
KRAS mutations status in patients with mCRC [3]. The test
is designed with primers to specifically detect mutations in
KRAS codons 12 and 13, since these codons account for the
majority of activating mutations (mutations in codons 12
and 13 account for *82 and *17 %, respectively, of all
reported KRAS mutations in exon 2) [17].
To expand the available IVD options for testing the anti-
EGFR therapy response of patients with mCRC, a study
was designed to compare the performance of the cobas
KRAS mutation test (hereafter referred to as the cobas test)
with that of Sanger sequencing and that of the therascreen
test.
Clinical utility of a new companion diagnostic test is
demonstrated when used within the context of a corre-
sponding clinical trial to identify the subpopulation of
patients who are most likely to benefit from an investiga-
tional drug. Alternatively, retrospective testing of patient
samples from the trial can be conducted to evaluate the
efficacy of the drug. For the cobas test, a potential com-
panion diagnostic for the treatment with cetuximab of
patients with mCRC, this approach was not feasible
because samples from the pivotal clinical trial were not
available and conducting a new randomized controlled trial
(with a placebo arm) to select patients using the cobas test
would be unethical.
Samples from another clinical cohort (bridging study
cohort) for CRC were tested by the cobas test and Sanger
sequencing as well as with another FDA-approved test (the
therascreen test). In the absence of clinical outcome data
for patients in the bridging study cohort, the drug efficacy
(estimated by hazard ratio [HR]) for cetuximab using the
cobas test was evaluated by transporting the drug efficacy
results from the pivotal study using a non-differential
misclassification (NDMC) assumption. Under this
assumption, the HR for the cobas wild-type and mutation-
positive subsets were assumed to be the same as the HR
conferred by the sequencing test result. The difference in
log HRs for the cobas test results can be estimated by
utilizing agreement between the cobas test and Sanger
sequencing. This difference was also estimated for the
FDA-approved test, and the result for the cobas test and the
FDA-approved test were compared.
The primary objective of this study was to determine
whether the analytical and clinical performance of the
cobas test was comparable to that of the FDA-approved
therascreen test in determining KRAS mutation status and
predicting clinical response to anti-EGFR therapy. The
study also aimed to demonstrate the clinical utility of the
cobas test to predict cetuximab and panitumumab efficacy
using a novel bridging analytical strategy.
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2 Materials and Methods
2.1 Study Design
The analytical performance of the cobas test was compared
with that of the therascreen test and Sanger sequencing for
detecting mutations in KRAS codons 12 and 13. Tissue
samples from the pivotal trials (NCIC-CO.17 [2, 3] and
NCT00113763 [10]) were not available at the time of this
study. Therefore, to assess analytical performance, forma-
lin-fixed, paraffin-embedded tissue (FFPET) samples from
the XELOXA (Xeloda and Oxaliplatin in Adjuvant Setting)
trial [18], which enrolled patients with stage III CRC and a
supplemental cohort of mCRC patient samples, were ana-
lyzed using both the cobas test and the therascreen test,
with Sanger sequencing performed on all samples as the
reference standard.
However, patients in the XELOXA trial were not treated
with cetuximab or panitumumab. Therefore, in the absence
of clinical outcome data from targeted therapy for patients
in the study, we used a bridging analytical strategy to
evaluate efficacy-based on data from separate trials [19].
Specifically, the drug efficacy of cetuximab and panitu-
mumab using the cobas test was evaluated by transporting
the HRs for each drug from two separate trials. The HRs
for cetuximab were based on the Sanger sequencing result
from the NCIC-CO.17 study [2], and the HRs for panitu-
mumab were based on the therascreen result from the
NCT00113763 study. Under an NDMC assumption, effi-
cacy was determined by performing bridging statistical
analyses [10]. In short, the HRs for the cobas wild-type and
mutation-positive subsets were assumed to be the same as
the HR conferred by the sequencing test result. The dif-
ference in log HRs for the cobas test results compared with
Sanger sequencing and the therascreen test was estimated
by utilizing agreement between the cobas test and Sanger
sequencing and between the cobas test and the therascreen
test, respectively. The positive and negative predictive
values (PPVs and NPVs, respectively) were estimated by
utilizing mutation prevalence from the NCIC-CO.17 study
and the NCT00113763 study. These estimates were then
used to calculate the attenuation factors for the cobas and
reference tests and are described in full in Sect. 2.8.
Additional analyses were performed (1) to demonstrate
the comparability of the clinical trial cohorts (covariate
analysis), (2) to evaluate the ‘‘influence criterion’’ and
sensitivity analyses, and (3) to evaluate the robustness of
the results.
This approach was necessary because it would have
been unethical to perform a randomized controlled trial
similar to those studies now that the relationship between
KRAS mutation status and cetuximab or panitumumab
efficacy in CRC patients is clear.
All specimens were sent to one external testing labora-
tory for KRAS mutation testing using the cobas test and the
therascreen test. A second clinical laboratory selected by
Roche Molecular Systems performed Sanger sequencing.
To reduce bias, all slides were coded by the sponsor to
mask the identity of individual patients and comparator
method results from the testing lab. Sample processing and
mutation testing were performed in accordance with the
respective manufacturer’s instructions for the cobas test
(Roche Molecular Systems, Inc., Peasanton, CA, USA) and
the therascreen test (Qiagen Inc., Valencia, CA, USA). The
study protocol was submitted to an Institutional Review
Board in accordance with FDA and local regulatory
requirements before the start of the study.
2.2 Study Population
Tumor specimens were obtained from 398 patients enrolled
between April 2003 and October 2004 in Roche study
NO16968 (XELOXA), a global, randomized, phase III
study conducted at approximately 226 sites worldwide
[18]. In addition, NO16968 samples were supplemented
with tumor specimens from 82 mCRC patients. From this
initial set of 480 screened samples, 461 eligible FFPET
samples were tested for KRAS mutations with the cobas
and therascreen tests, since 15 samples had no tumor
content and four were not CRC, as confirmed by pathology
evaluation. Additionally, all 461 samples underwent San-
ger DNA sequencing as the reference method. Eligible
patients were aged at least 18 years and had histologically
confirmed, late-stage CRC. Sufficient archival FFPET
material had to be available for mutation analysis, and
written informed consent was obtained from all patients or
their legal guardian. Patients were excluded if there was
insufficient material to perform testing with the cobas test,
the therascreen test, and Sanger sequencing.
2.3 Tumor Block Sectioning and Pathology
Assessment
FFPET blocks were sectioned and ten serially cut 5-lm
sections were mounted on slides with one section per slide.
Four of ten slides were designated for cobas testing and
four were designated for therascreen testing. All slides
were coded by laboratory personnel to mask the identity of
the individual patients. One slide from the middle of the
serial sections underwent hematoxylin and eosin (H&E)
staining. A laboratory pathologist used the H&E-stained
slide to determine the percentage tumor cell content by
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area. Manual macro-dissection was required if tumor cell
content by area was\10 % for the cobas test and\20 %
for the therascreen test. One of the ten slides was saved as
back-up for each of the assays, whereas one was reserved
for H&E testing and four slides each were reserved for the
cobas test and the therascreen test and for repeat testing, if
necessary (i.e., in the event of an invalid result).
2.4 cobas Test Protocol
The cobas KRAS Mutation Test kit (cobas test) is a
TaqMeltTM-based polymerase chain reaction (PCR) assay
[20, 21] based on two major processes: (1) manual speci-
men preparation to obtain genomic DNA from FFPET
using the cobas DNA Sample Preparation Kit; and (2) PCR
amplification of target DNA. The test is designed to detect
19 mutations in codons 12 and 13 of exon 2 and 61 of exon
3 of the KRAS gene. However, because of the lack of a
predicate device for codon 61, we compared the cobas test
performance for only codons 12/13.The cobas test has a
C95 % correct mutation call rate across all specimen types
with *5 % mutant alleles at a DNA input of 0.8–6.3 ng/
PCR [20].
Genomic DNA was isolated from at least one slide
designated for the cobas test. DNA isolation was performed
using the cobas test manufacturer’s instructions to ensure
that sufficient DNA was recovered. If the concentration of
DNA obtained from a slide was C4 ng/ll, testing with the
cobas test was performed. If the concentration of the
purified sample was\4 ng/ll, DNA isolation was repeated
using two slides. Tissue from these two slides was added to
one tube and DNA isolation and testing with the cobas test
was performed if the concentration of DNA obtained was
C4 ng/ll. All residual DNA stock from the sample
preparation process was quantified and stored at –20 C for
future shipment to a separate clinical laboratory where all
samples underwent Sanger sequencing.
2.5 therascreen Test Protocol
The therascreen KRAS RGQ PCR Kit (therascreen test) is
a real-time PCR assay that combines an amplification
refractory mutation system (ARMS) and a Scorpion fluo-
rescent primer/probe system [22]. The therascreen test has
high sensitivity (*1 % mutant allele), but requires
[160 ng of amplifiable DNA (equivalent to 800 ng of the
total DNA input) and eight PCR reactions to detect the
seven most common mutations in codons 12 and 13 of the
KRAS gene and may not detect uncommon KRAS muta-
tions [22, 23]. Genomic DNA was isolated from at least
one slide from each patient designated for therascreen
testing. DNA was isolated using the QIAamp DSP DNA
FFPE Tissue Kit (Qiagen, Inc.) and then tested with the
therascreen test, according to the manufacturer’s instruc-
tions. Based on the therascreen test package insert, a PCR-
based sample-assessment step for DNA quality was per-
formed prior to the mutation detection round. Based on the
assessment step, samples could be designated as adequate
for testing, interpret with caution because of low levels of
DNA, very few amplifiable copies of DNA, or reject
sample. Mutation calls were based on the manufacturer’s
recommendations using a delta Ct method.
2.6 Sanger DNA Sequencing
After a valid cobas test result was confirmed, residual DNA
from the cobas test sample-preparation process was com-
bined with DNA extracted and quantified from the
remaining slides as needed to achieve a minimum of 5 ll
DNA with a DNA concentration C10 ng/ll. DNA stock
intended for sequencing was shipped at –20 C to a sepa-
rate clinical laboratory selected by Roche Molecular
Systems.
2.7 Agreement Analysis and Statistics
All analyses were performed using SAS Enterprise Guide
software version 5.1 (SAS Institute, 2012). Mutation
detected (MD) was defined as the presence of KRAS
mutations in codons 12 and/or 13 and no mutation detected
(NMD) was defined as the absence of KRAS mutations in
codons 12 and 13.
The analytical performance of the cobas test compared
with the therascreen test and the reference method (Sanger
sequencing) for detection of codon 12 and 13 mutations
was evaluated by positive, negative, and overall percent
agreement (PPA, NPA, and OPA) with 2-sided 95 %
confidence intervals (CIs).
2.8 Analyses of Clinical Effectiveness of cobas Test
In concordance with recommendations from FDA, the
following five criteria were used to establish the clinical
utility of the cobas test, specifically, the ability of the cobas
test to select patients who are likely to benefit from treat-
ment with cetuximab or with panitumumab:
1. Attenuation factors for cobas test
2. Attenuation factors for reference KRAS test




The first three criteria were evaluated using a key
assumption that the drug efficacy (of cetuximab or pani-
tumumab) using the cobas test is non-differential given the
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reference method result. This assumption leads to the fol-
lowing relationships based on the PPV and NPV estimated
from initial studies:
1. Difference in log HR for cobas test = difference in log
HR for reference method MD and NMD
result 9 (NPV ? PPV - 1) was calculated as
follows:
d0: d1: ¼ ðd:0  d:1Þ  ðp1  p0Þ;
here d0. = log(HR) for cobas test NMD result,
d1. = log(HR) for cobas test MD result, d.0 = log(HR) for
Sanger NMD result, d.1 = log(HR) for Sanger MD result,
p1 = PPA; po = 1–NPA
2. Log HR for cobas KRAS MD result = log HR for
reference method MD result 9 PPV ? log HR for
reference method NMD result 9 (1 - PPV)
3. Log HR for cobas KRAS NMD result = log HR for
reference method MD result 9 (1 - NPV) ? log HR
for reference method NMD result 9 NPV
Criteria 1 and 2 The attenuation factors for the cobas
test and reference test were calculated by the quantity
PPV ? NPV - 1. The predictive values of the cobas test
were calculated by combining the PPA and NPA of the
cobas test relative to a reference method together with the
prevalence of a KRAS MD result by the reference method
in the published clinical studies for cetuximab or panitu-
mumab [2, 10]. The formulas for PPV and NPV are as
follows:
PPV ¼ sp1 þ 1 sð Þp0;
here p1 ¼ PPA; p0 ¼ 1 NPA;
s ¼ mutation prevalence in the pivotal study
NPV ¼ sð1 p1Þ=sð1 p1Þ þ 1 sð Þð1 p0Þ
The estimates and CIs were calculated using the
parametric bootstrap method.
Criterion 3 The clinical effectiveness of the cobas test,
measured by HR, to select mCRC patients for treatment
with cetuximab or panitumumab was supported by
demonstrating significant efficacy in the KRAS NMD
population and lack of significant efficacy in the KRAS MD
population based on PFS, with supplementary analysis of
OS. Drug efficacy for cetuximab or panitumumab using the
cobas test was evaluated by transporting the drug efficacy
results from the pivotal study NCIC-CO.17 and
NCT00113763, respectively, under the NDMC assumption.
The estimate of the HR for the cobas test for the NMD
and MD cohorts and the difference of the log HR and their
corresponding 95 % CIs were estimated using a parametric
bootstrap method.
Criterion 4 The distribution of covariates between
XELOXA and the supplemental samples and NCIC-CO.17
for cetuximab (or NCT00113763 for panitumumab) were
compared. Drug efficacy was re-evaluated after adjusting
for covariates, which were significantly different between
the two studies.
Criterion 5 A sensitivity analysis was performed to
determine how many agreements between cobas testing
and Sanger sequencing would have to be changed to dis-




The median age of the 480 enrolled patients was 61 years
(range 26–89). Approximately 89 % of patients were
Caucasian and 54 % were male; 95 % of patients had an
Eastern Cooperative Oncology Group (ECOG) score of 0
or 1 and 98 % had stage III disease. The vast majority of
tissue samples were from primary tumors, with the
remaining 3 % being metastatic (Table 1). A total of 86 %
of tumor specimens contained at least 20 % tumor cells,
and 54 % had no tumor necrosis. Patient demographics and
baseline characteristics are shown in Table S1 in the
Electronic Supplementary Material (ESM).
3.2 KRAS Mutation Analysis: Invalid Samples
and Mutation Detection Rates
All of the 461 eligible samples were tested by the cobas
test, the therascreen test, and Sanger sequencing. Speci-
mens for which the codon 12/13 reaction well was invalid
or for which an out-of-range melting temperature or peak
height was observed (neither wild-type nor mutant range)
were reported as ‘invalid’. The cobas test had an invalid
rate of 5.2 %, the therascreen test had an invalid rate of
10.8 %, and Sanger sequencing had an invalid rate of
2.6 % (Table 2). The therascreen invalid rate included 8 %
DNA sample assessment failures and 2.8 % mutation
testing failures. If the initial test result was invalid,
retesting by the cobas test or therascreen was performed up
to two times; however, re-testing was not limited unless
there was insufficient remaining sample DNA for Sanger
sequencing. Among the samples with valid results, the
cobas and therascreen tests had similar KRAS mutation-
positive rates (37.3 vs. 36.3 %, respectively), while Sanger
sequencing had a positive rate of 28.5 %.
3.3 Analytical Performance
The analytical performance of the cobas test was compared
with Sanger sequencing or the therascreen test for the
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ability to detect mutations in KRAS codons 12 and 13 in
CRC tumor samples by determining PPA, NPA, and OPA.
Results are shown in Table 3. The four samples where
Sanger sequencing identified mutations in KRAS but the
cobas test missed them were also missed by therascreen. Of
34 samples where the cobas test detected codon 12/13
mutations and Sanger sequencing missed, 26 were con-
firmed as codon 12/13 mutations by therascreen. When
comparing the cobas and therascreen tests, the cobas test
missed mutations in ten samples called codon 12/13
mutations by therascreen. All these samples were con-
firmed as mutation not detected by Sanger sequencing. Of
Table 1 Baseline tumor
characteristics and specimen
availability
Characteristics Overall (n = 480) XELOXA samples (n = 398) Supplemental samples (n = 82)
Tumor type
Primary 463 (96.5) 394 (99.0) 69 (84.1)
Metastatic 12 (2.5) 0 (0) 12 (14.6)
Unknown 5 (1.0) 4 (1.0) 1 (1.2)
Tumor contents
\10 % 26 (5.4) 25 (6.3) 1 (1.2)
10–20 % 42 (8.8) 38 (9.5) 4 (4.9)
[20 % 412 (85.8) 335 (84.2) 77 (93.9)
Necrosis
No necrosis 261 (54.4) 225 (56.5) 36 (43.9)
\10 % 76 (15.8) 59 (14.8) 17 (20.7)
C10 % 143 (29.8) 114 (28.6) 29 (35.4)
All data are presented as n (%)
Table 2 Invalid sample rates
and mutation detection rates
from the three testing methods
cobas test therascreen test Sanger sequencing
Samples tested (n) 461 461 461
Invalid result 24 (5.2) 50 (10.8) 12 (2.6)
Valid result 437 (94.8) 411 (89.2) 449 (97.4)
No mutation detected 274 (62.7) 262 (63.7) 321 (71.5)
Mutation detected 163 (37.3) 149 (36.3) 128 (28.5)
All data are presented as n (%) unless otherwise indicated














MD 124 34 5 163 139 9 15 163
MND 4 268 2 274 10 248 16 274
Invalid 0 19 5 24 0 5 19 24
Total 128 321 12 461 149 262 50 461
PPAa 96.9 % (124/128) [92.2–98.8] 93.3 % (139/149) [88.1–96.3]
NPAa 88.7 % (268/302) [84.7–91.8] 96.5 % (248/257) [93.5–98.1]
OPAa 91.2 % (392/430) [88.1–93.5] 95.3 % (387/406) [92.8–97.0]
CI confidence interval MD mutation detected, MND mutation not detected, NPA negative percentage agreement, OPA overall percentage
agreement, PPA positive percentage agreement
a Data are presented as % (n/N) [95% CI]
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the nine samples called MD by cobas and NMD by ther-
ascreen, six samples were NMD and three were MD by
Sanger sequencing. The PPA/NPA between the cobas test
and Sanger sequencing was 96.9 % (95 % CI 92.2–98.8)
and 88.7 % (95 % CI 84.7–91.8), respectively. The PPA/
NPA between the cobas and therascreen tests was 93.3 %
(95 % CI 88.1–96.3) and 96.5 % (95 % CI 93.5–98.1),
respectively. The PPA between therascreen and Sanger
sequencing was 94.2 % (113/120) and the NPA was
87.5 % (253/289).
Since Sanger sequencing is less sensitive than both the
cobas and the therascreen tests, the lower NPA between the
cobas test and Sanger sequencing (88.7 %; 268 of 302
samples; 95 % CI 84.7–91.8) was expected. The improved
NPA between the cobas and therascreen tests (96.5 %; 248
of 257 samples; 95 % CI 93.5–98.1) supports this
expectation.
3.4 Clinical Utility
3.4.1 Attenuation Factor Evaluation
Clinical effectiveness of the cobas test was established by
modeling the difference in the log HR from the pivotal
clinical trials for cetuximab and panitumumab. Under the
NDMC assumptions, the difference in log HR between
NMD and MD populations was projected to be attenuated
relative to the corresponding difference for the comparator
method by the factor (PPV ? NPV - 1). The attenuation
factor refers to the fraction of expected difference in
response that is preserved when the new test is used instead
of the reference test.
The attenuation factors (PPV ? NPV - 1) for cobas
versus the reference methods are shown in Table 4, which
indicated that the difference in the log HRs of the cobas
test NMD and MD subsets was projected to be
83.3–90.4 % of the corresponding difference for the
reference method. The attenuation factor for the ther-
ascreen test versus Sanger sequencing was 79.5 %, which
indicated that only approximately 80 % of the difference in
log HR was preserved from the drug efficacy based on
Sanger sequencing.
3.4.2 Estimated Efficacy of Anti-Epidermal Growth Factor
Receptor (EGFR) Therapy by cobas Test
For cetuximab, the HRs for PFS and OS in patients with
wild-type KRAS were estimated to be 0.413 (95 % CI
0.304–0.550) and 0.558 (95 % CI 0.422–0.752) (Table 5).
These HRs indicated that PFS and OS were both signifi-
cantly improved in a CRC population of KRAS NMD as
determined by the cobas test. For the KRAS MD population
selected by the cobas test, the HRs for PFS and OS were
0.869 (95 % CI 0.670–1.138) and 0.908 (95 % CI
670–1.209), indicating that PFS and OS were not improved
in a CRC patient population with mutated KRAS as deter-
mined by the cobas test.
Similarly, the estimated HRs for PFS in the KRAS NMD
and KRAS MD populations identified by the cobas test
were estimated to be 0.471 (95 % CI 0.360–0.626) and
0.964 (95 % CI 0.709–1.293), respectively, for panitu-
mumab. These HRs indicate that PFS was significantly
improved in CRC patients with wild-type KRAS status and
not improved in patients with mutated KRAS status.
3.4.3 Covariate Assessment and Sensitivity Analysis
Tables evaluating sample attribute covariates and sensi-
tivity analysis are presented in the ESM (Tables S2–S5).
Covariate analysis showed some significant sample-type
characteristic differences between the bridging cohort and
the trial cohorts, including Duke’s stage (Table S2 in the
ESM); however, KRAS mutation status appears to occur at
a relatively constant rate regardless of clinical stage [24,
Table 4 Attenuation factors (PPV ? NPV - 1) for the cobas KRAS mutation test
Comparison Drug Codon 12/13
prevalence
in the pivotal study
(%)
PPV NPV Attenuation factor
cobas test vs. Sanger sequencing Cetuximab 41.6 0.858 (0.811–0.902) 0.975 (0.946–0.994) 83.3 % (77.7–88.3)
cobas test vs. therascreen test Cetuximab 41.6 0.957 (0.927–0.981) 0.945 (0.909–0.978) 90.2 % (85.6–94.4)
cobas test vs. therascreen test Panitumumaba 40.1 0.949 (0.914–0.977) 0.956 (0.927–0.981) 90.4 % (86.1–94.4)
therascreen test vs. Sanger
sequencing
Cetuximab 41.6 0.840 (0.790–0.888) 0.956 (0.918–0.986) 79.5 % (73.4–85.2)
Data in parentheses are 95 % CIs
CI confidence interval, NPV negative predictive value, PPV positive predictive value
a Samples in the NCT00113763 trial for panitumumab were only tested by the therascreen test
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25] and primary tumors are often used to determine KRAS
status for ‘intention-to-treat’ patients [17, 26]. The sensi-
tivity analysis showed that the bridging comparison was
robust since the estimated HRs for OS and PFS for the MD
population decreased to\1.0 (with an upper limit of the
95 % CI of 0.99) only after the frequency of discordance
exceeded 21 % and 12.6 % beyond the measured discor-
dance, respectively (Table S5 in the ESM).
4 Discussion
The study was undertaken to evaluate the performance of
the cobas test in selecting advanced CRC patients for
treatment with cetuximab and panitumumab. Determina-
tion of KRAS mutation status is recommended by the
NCCN guidelines [14] to select appropriate treatment for
patients with mCRC. Using bridging statistical analysis
[19] and NDMC assumption to impute efficacy from the
pivotal phase III clinical trials CO.17 for cetuximab and
NCT0013763 for panitumumab, the results demonstrate
that the cobas test shows similar accuracy to the ther-
ascreen test for detecting KRAS mutations in CRC FFPET
samples for the treatment decision.
The study design was determined by the fact that CRC
tumor specimens from the therascreen pivotal trial, CO.17,
were unavailable. Moreover, it would have been unethical
to perform a clinical trial with the same design as the
CO.17 trial, which used BSC in one of the two treatment
arms. Therefore, in close collaboration with FDA, the
current study design was adopted. The study analyzed
KRAS mutations in CRC tumor specimens from the Roche
clinical trial NO16968 (XELOXA) because the clinical
attributes from patients in the XELOXA trial were similar
to those used in both pivotal trials. The cobas test
demonstrated an analytical performance that was compa-
rable to that of the therascreen test based on PPA, NPA,
and OPA. The differences in analytical performance noted
between the cobas and therascreen tests could be due to
uncommon KRAS mutations that will not be detected by the
therascreen design (in the case of the nine samples called
MD by cobas and MND by therascreen), while low tumor
cellularity (\10 %) could be the reason the cobas test
missed mutations in ten samples called codon 12/13
mutations by therascreen. Clinical utility of the cobas test
was demonstrated by showing maintenance of cetuximab
and panitumumab treatment efficacy in the KRAS NMD
patient population and the lack of treatment efficacy in the
KRAS MD patient population—those with mutations in
KRAS codons 12 and 13. The cobas test and the therascreen
test are essentially comparable in their ability to correctly
select patient populations for either prescribing or with-
holding cetuximab or panitumumab treatment based on the
absence or presence, respectively, of mutations in KRAS
codons 12 and 13. In another study comparing the cobas
and therascreen tests and Sanger sequencing, the cobas test
was demonstrated to have greater analytic sensitivity in
detecting KRAS mutations than Sanger sequencing and also
detected more uncommon KRAS mutations than the ther-
ascreen test with a lower sample input volume (100 ng of
total DNA input with the cobas test vs. 800 ng of total
DNA with the therascreen test) due to its broader
reportable range [22].
In the current study, a lower attenuation factor for
therascreen versus Sanger sequencing was noted. This is
expected as, among the three assays, Sanger sequencing
has the lowest analytic sensitivity [22]. Low tumor cellu-
larity of specimens could lead to false-negative results with
Sanger sequencing [23] and would require more sensitive
assays for mutation detection. In the current study, 26
samples were recorded as KRAS NMD with Sanger
sequencing and MD with the cobas test (and confirmed MD
with the therascreen test); the negative results with Sanger
sequencing could possibly be due to poor analytical sen-
sitivity of the method. For Sanger sequencing, residual
DNA from the cobas sample preparation process was
combined with DNA extracted and quantified from the
remaining slides as needed to obtain the required sample
processing volume. This meant that samples undergoing
Sanger sequencing were macro-dissected in accordance
with the cobas test package insert instructions, i.e., macro-
dissection was required for specimens with tumor cell
content by area of\10 %. If macro-dissection had been
performed for the 42 specimens with tumor cell content by
Table 5 Estimated drug efficacy by KRAS mutation status
Efficacy outcome cobas KRAS mutation status Cetuximab HR (95 % CI) Panitumumab HR (95 % CI)
PFS NMD 0.413 (0.304–0.550) 0.471 (0.360–0.626)
MD 0.869 (0.670–1.138) 0.964 (0.709–1.293)
OS NMD 0.558 (0.422–0.752) 0.989 (0.778–1.299)
MD 0.908 (0.670–1.209) 1.027 (0.767–1.375)
CI confidence interval, HR hazard ratio, MD mutation detected, NMD no mutation detected, OS overall survival, PFS progression-free survival
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area of 10–20 %, it is possible that the mutation detection
rate with cobas and Sanger sequencing could have been
improved. The four samples where Sanger sequencing
identified mutations in KRAS but the cobas test missed
them were also missed by therascreen because of uncom-
mon KRAS mutations that are not detected by the cobas and
therascreen designs.
The study design of the panitumumab pivotal trial
(NCT0013763) was very similar to that of the cetuximab
trial (CO.17) [2, 10]. Both studies evaluated efficacy of the
anti-EGFR antibody versus BSC in patients with advanced
CRC. The one striking difference was that, in the panitu-
mumab pivotal trial, patients randomized to BSC were
allowed to cross over to panitumumab upon progression.
This difference affected the HRs for OS, which showed a
non-significant difference between the two treatments. The
results indicate that the influence condition does not hold
due to improved drug efficacy in the KRAS NMD popu-
lation and no improvement in the KRAS MD population as
selected by cobas testing.
Some of the challenges with the current study are that
the true clinical performance of the cobas test relative to
the other methods has not been prospectively tested, the
patient cohort represented stage III and IV patients, and
invalid and discrepant results were not sufficiently
resolved. Because the efficacy of anti-EGFR therapy has
been demonstrated to have significant benefit in patients
with KRAS wild-type mutations, it would be unethical to
withhold therapy for such patients. Conversely, treatment
of patients with KRAS mutants with anti-EGFR therapy
leads to no benefit and can have a potential negative impact
on survival. Therefore, we evaluated samples from primary
tumors of patients with stage III and IV disease. For
patients who have tumors excised with curative intent in
stage III disease, that tissue is often used to establish KRAS
mutation status prior to or at the time of disease recurrence
or after progression when treated with anti-angiogenic
therapies such as bevacizumab. Finally, discrepant cases
may be due to the different methods, tumor heterogeneity,
or varying sensitivity for the assays. Invalid cases for either
technology may have been a function of the quality of the
sections or the methods used for DNA isolation or the
handling of the sample. In clinical practice, when an
invalid result occurs, the testing laboratory would repeat
the assay or use an alternative technology. Any diagnostic
test is prone to invalid results, but the workflow and ease of
use for the cobas test, along with the low invalid rate,
would likely be manageable. Another potential reason for
invalid results could be the age of the tissue blocks or
oxidation of the tissue. In routine practice, patients with
freshly prepared FFPET blocks may encounter fewer
invalid results than in this retrospective study.
The study indicates that the HRs for PFS and OS from
patients with wild-type versus mutated KRAS are equally
comparable between the cobas test and another FDA-ap-
proved test. This novel approach to test validation using a
bridging analytical strategy demonstrated that the cobas
test could appropriately identify patients with mCRC
ineligible for anti-EGFR therapy.
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